Literature DB >> 10995787

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

T Kurihara1, D E Brough, I Kovesdi, D W Kufe.   

Abstract

The DF3/MUC1 gene is aberrantly overexpressed in human breast and other carcinomas. Previous studies have demonstrated that the DF3/MUC1 promoter/enhancer confers selective expression of diverse transgenes in MUC1-positive breast cancer cells. In this study, we show that an adenoviral vector (Ad.DF3-E1) in which the DF3/MUC1 promoter drives expression of E1A selectively replicates in MUC1-positive breast cancer cells. We also show that Ad.DF3-E1 infection of human breast tumor xenografts in nude mice is associated with inhibition of tumor growth. In contrast to a replication-incompetent adenoviral vector that infects along the injection track, Ad.DF3-E1 infection was detectable throughout the tumor xenografts. To generate an Ad.DF3-E1 vector with the capacity for incorporating therapeutic products, we inserted the cytomegalovirus (CMV) promoter upstream of the TNF cDNA. Infection with Ad.DF3-E1/CMV-TNF was associated with selective replication and production of TNF in cells that express MUC1. Moreover, treatment of MUC1-positive, but not MUC1-negative, xenografts with a single injection of Ad.DF3-E1/CMV-TNF was effective in inducing stable tumor regression. These findings demonstrate that the DF3/MUC1 promoter confers competence for selective replication of Ad.DF3-E1 in MUC1-positive breast tumor cells, and that the antitumor activity of this vector is potentiated by integration of the TNF cDNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995787      PMCID: PMC381391          DOI: 10.1172/JCI9180

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.

Authors:  S Miyatake; R L Martuza; S D Rabkin
Journal:  Cancer Gene Ther       Date:  1997 Jul-Aug       Impact factor: 5.987

2.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Authors:  R Rodriguez; E R Schuur; H Y Lim; G A Henderson; J W Simons; D R Henderson
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

3.  Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver.

Authors:  J T Bruder; T Jie; D L McVey; I Kovesdi
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.

Authors:  C Heise; A Sampson-Johannes; A Williams; F McCormick; D D Von Hoff; D H Kirn
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

5.  Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter.

Authors:  L Chen; D Chen; Y Manome; Y Dong; H A Fine; D W Kufe
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

Authors:  A J Bett; W Haddara; L Prevec; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Authors:  J R Bischoff; D H Kirn; A Williams; C Heise; S Horn; M Muna; L Ng; J A Nye; A Sampson-Johannes; A Fattaey; F McCormick
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

8.  Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir.

Authors:  Y Manome; M Abe; M F Hagen; H A Fine; D W Kufe
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

9.  Analysis of the tissue-specific promoter of the MUC1 gene.

Authors:  A Kovarik; N Peat; D Wilson; S J Gendler; J Taylor-Papadimitriou
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

10.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

View more
  41 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.

Authors:  C-Q Su; J Sham; H-B Xue; X-H Wang; D Chua; Z-F Cui; L-H Peng; L-F Li; L-H Jiang; M-C Wu; Q-J Qian
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-09       Impact factor: 4.553

3.  High promoter activity of cytokeratin-19 gene in cholangiocarcinoma.

Authors:  Jian Qin; Min Wang; Jun Qin; Qu Cai; Zhi-Hai Peng
Journal:  Mol Clin Oncol       Date:  2018-08-16

4.  Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.

Authors:  W Zhou; S Dai; H Zhu; Z Song; Y Cai; J B Lee; Z Li; X Hu; B Fang; C He; X Huang
Journal:  Gene Ther       Date:  2017-01-11       Impact factor: 5.250

5.  Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma.

Authors:  Chang-Qing Su; Xing-Hua Wang; Jie Chen; Yong-Jing Liu; Wei-Guo Wang; Lin-Fang Li; Meng-Chao Wu; Qi-Jun Qian
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

6.  Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.

Authors:  Chen Liu; Bin Sun; Ni An; Weifeng Tan; Lu Cao; Xiangji Luo; Yong Yu; Feiling Feng; Bin Li; Mengchao Wu; Changqing Su; Xiaoqing Jiang
Journal:  Mol Oncol       Date:  2011-10-19       Impact factor: 6.603

7.  Transcriptional control of viral gene therapy by cisplatin.

Authors:  James O Park; Carlos A Lopez; Vinay K Gupta; Charles K Brown; Helena J Mauceri; Thomas E Darga; Abdullah Manan; Samuel Hellman; Mitchell C Posner; Donald W Kufe; Ralph R Weichselbaum
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 8.  Transcriptionally targeted gene therapy to detect and treat cancer.

Authors:  Lily Wu; Mai Johnson; Makoto Sato
Journal:  Trends Mol Med       Date:  2003-10       Impact factor: 11.951

9.  Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

Authors:  M Takakura; M Nakamura; S Kyo; M Hashimoto; N Mori; T Ikoma; Y Mizumoto; T Fujiwara; Y Urata; M Inoue
Journal:  Cancer Gene Ther       Date:  2010-01       Impact factor: 5.987

10.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.